Dapagliflozin: a review of its use in type 2 diabetes mellitus (Q34313024)

1 August 2017

1 reference

title

Dapagliflozin: a review of its use in type 2 diabetes mellitus (English)

1 reference

1 August 2017

0 references

1

Greg L Plosker

1 reference

1 August 2017

1 December 2012

1 reference

1 August 2017

1 reference

1 August 2017

72

1 reference

1 August 2017

2289-2312

1 reference

1 August 2017

17

1 reference

https://scigraph.springernature.com/pub.10.2165/11209910-000000000-00000

1 August 2017

0 references

cites work

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

12 December 2020

Standards of medical care in diabetes--2012

1 reference

12 December 2020

Mortality attributable to diabetes: estimates for the year 2010.

1 reference

12 December 2020

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

1 reference

12 December 2020

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

1 reference

12 December 2020

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

12 December 2020

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

1 reference

12 December 2020

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

12 December 2020

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

1 reference

12 December 2020

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

1 reference

12 December 2020

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

1 reference

12 December 2020

Global estimates of the prevalence of diabetes for 2010 and 2030

1 reference

12 December 2020

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

1 reference

12 December 2020

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

1 reference

12 December 2020

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study

1 reference

12 December 2020

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

1 reference

12 December 2020

Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin

1 reference

12 December 2020

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

12 December 2020

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

1 reference

12 December 2020

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

1 reference

12 December 2020

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

1 reference

12 December 2020

Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

1 reference

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

12 December 2020

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

12 December 2020

Diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

Management of type 2 diabetes: new and future developments in treatment

1 reference

12 December 2020

Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey.

1 reference

12 December 2020

Surprising versatility of Na+-glucose cotransporters: SLC5.

1 reference

12 December 2020

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

1 reference

12 December 2020

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

The association of glycemia and cause-specific mortality in a diabetic population

1 reference

12 December 2020

The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function.

1 reference

12 December 2020

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

1 reference

12 December 2020

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

1 reference

12 December 2020

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

12 December 2020

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

1 reference

12 December 2020

10.2165/11209910-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

23170914

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

23170914